We are pleased to announce that our DeepChek® Assay 13-Plex KB Drug Susceptibility Testing, intended to be used for Tuberculosis Drug Resistance assessment through NGS sequencing, is now CE-IVD marked !

We are pleased to announce a new poster presentation entitled “Evaluation of a commercial assay whole genome HIV-1 using next-generation sequencing” at ECCMID 2022.

Link to the poster presentation.

Please feel free to contact us to get more information.

ETABLISSEMENTS FAUVET GIREL (FR0000063034 – FAUV – Euronext Paris) publie ses résultats annuels au titre de l’exercice clos le 31 décembre 2021, arrêtés par le Conseil d’administration du 8 février 2022. Les comptes ont été audités par le commissaire aux comptes dont le rapport de certification est en cours d’émission.

Résultats annuels 2021

ETABLISSEMENTS FAUVET GIREL n’a plus d’activité opérationnelle depuis la cession de son activité de location de conteneurs et de wagons pour le fret ferroviaire en 2018 et ne détient plus aucun actif depuis la cession de son dernier actif immobilier situé à Meudon en avril 2021.

Les comptes sociaux de l’exercice écoulé font apparaitre un résultat net de 257 868 €, intégrant un résultat exceptionnel de 398 568 € lié à la cession de son dernier actif immobilier, contre une perte de (89 296) € pour l’exercice précédent.

Le total du bilan s’élève à 2 713 363 € contre 2 379 334 € pour l’exercice précédent.

L’endettement financier de la Société n’est pas significatif (intérêts courus à payer). La trésorerie d’exploitation d’un montant de 2 702 442 € au 31 décembre 2021 permet d’acquitter les dettes de la Société à échéance.

Perspectives – Opération de fusion-absorption au cours du 1^er semestre 2022

Comme annoncé par la société Advanced Biological Laboratories SA lors de l’acquisition d’un bloc de contrôle de la Société, puis dans le cadre de l’offre publique d’achat simplifiée visant les actions de la Société, le projet de fusion-absorption de la société Advanced Biological Laboratories Fedialis (« ABL France ») par Etablissements Fauvet Girel est en cours de préparation, en vue d’une réalisation d’ici la fin du 1^er semestre 2022.

Dans ce cadre, les actionnaires de la Société seront appelés à approuver en assemblée générale la fusion-absorption. L’admission des actions qui résulteront de cette opération sera conditionnée à l’approbation d’un prospectus par l’Autorité des marchés financiers.

A propos d’ETABLISSEMENTS FAUVET GIREL

ETABLISSEMENTS FAUVET GIREL est cotée sur Euronext Paris, compartiment C (ISIN FR0000063034).

Plus d’informations sur www.fauvet-girel.com.

Contacts

ETABLISSEMENTS FAUVET-GIREL

+33 (0)1 56 88 20 40

fauvet-girel@ablsa.com

Advanced Biological Laboratories (ABL) S.A. and Geneplus Co Ltd are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Thailand.

See current channel partners.

Advanced Biological Laboratories (ABL) S.A. and Hayleys Lifesciences  are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Sri Lanka.

See current channel partners.

Résultat de l’offre publique d’achat simplifiée visant les actions de la société ETABLISSEMENTS FAUVET-GIREL, initiée par ADVANCED BIOLOGICAL LABORATORIES SA

L’offre publique d’achat simplifiée visant les actions ETABLISSEMENTS FAUVET-GIREL, initiée le
23 décembre 2021 par ADVANCED BIOLOGICAL LABORATORIES SA (« ABL SA »), s’est clôturée le 7 janvier 2022. A l’occasion de cette offre, ABL SA a acquis 954 actions représentant 0,38% du capital et 0,38% des droits de vote de la société ETABLISSEMENTS FAUVET-GIREL.

À la clôture de l’offre publique d’achat simplifiée, ABL SA détient 243.481 actions ETABLISSEMENTS FAUVET-GIREL représentant autant de droits de vote, soit 97,08% du capital et des droits de vote de cette société.

 Le règlement-livraison de l’offre interviendra selon le calendrier communiqué par Euronext Paris.

Calendrier envisagé

A la suite de l’offre publique d’achat simplifiée, ABL SA va engager dans les prochaines semaines les opérations de transfert de l’activité d’ABL France (filiale à 100% d’ABL SA) à la société ETABLISSEMENTS FAUVET-GIREL, en vue d’une réalisation des opérations de transfert d’activité au cours du premier semestre 2022. Les actionnaires de la société ETABLISSEMENTS FAUVET-GIREL seront ainsi appelés à approuver en assemblée générale l’opération aux termes de laquelle les activités de la société ABL France seront transférées à la société ETABLISSEMENTS FAUVET-GIREL. La société ABL France aura vocation à être par la suite absorbée par la société ETABLISSEMENTS FAUVET-GIREL, qui aura été renommée ABL DIAGNOSTICS. L’admission des actions qui résulteront des opérations de transfert sera conditionnée à l’approbation d’un prospectus par l’AMF.

Le transfert d’ABL France à la société ETABLISSEMENTS FAUVET-GIREL et la réorientation de l’activité de la société ETABLISSEMENTS FAUVET-GIREL en résultant seront par ailleurs assorties d’une demande de dérogation au dépôt d’une offre publique de retrait sur le fondement de l’article 236-6 du règlement général de l’AMF.

À propos de ETABLISSEMENTS FAUVET-GIREL

 ETABLISSEMENTS FAUVET-GIREL est une société cotée sur Euronext Paris (Compartiment C) qui n’exerce plus aucune activité à la date des présentes et ne détient aucun actif autre que la trésorerie résiduelle dans ses comptes.

ETABLISSEMENTS FAUVET GIREL – Code ISIN : FR0000063034

À propos de ADVANCED BIOLOGICAL LABORATORIES (« ABL SA »)

 Advanced Biological Laboratories (ABL), S.A., est une société de diagnostic médical fondée en 2000 en tant que spin-off de CRP-Santé (https://www.lih.lu/) Luxembourg.

Les produits d’ABL SA sont dédiés aux cliniciens spécialisés en maladies infectieuses, aux laboratoires de virologie et de microbiologie, avec notamment :

• des kits de génotypage (au sein de ABL France) et des logiciels pour les laboratoires accrédités (ISO 15189), principalement pour les applications de microbiologie (liées au VIH, au SARS-CoV-2, à la tuberculose, au VHC, au VHB, au VPH, au CMV, à la grippe, à l’ARN 16s…) pour le génotypage par séquençage capillaire ou haut débit (DeepChek®), la détection et la quantification d’ADN et d’ARN (UltraGene®) ;
• des applications logicielles cliniques pour les unités de soins de maladies infectieuses ;
• des tableaux de bord informatiques et applications d’agrégation de bases de données cliniques pour la recherche et la gestion

ABL SA a acquis en 2013 les droits sur tous les actifs liés aux hépatites virales B & C d’EVIVAR MEDICAL ainsi qu’un système de dossier médical électronique personnalisé pour les maladies infectieuses de GlaxoSmithKline en 2016. En juillet 2018, a acquis CDL Pharma pour développer des CRO liés services et capacité de fabrication de kits diagnostic. En juin 2019, ABL SA a créé sa filiale aux USA (AdvancedDx Biological Laboratories) couvrant l’ensemble du territoire nord-américain. Cette filiale commercialise les produits ABL SA à visée de la Recherche (RUO – Research Use Only / IUO – Investigational Use Only) mais aussi les produits ABL SA déjà enregistrés auprès de la FDA.

ABL SA propose une suite complète de produits de gestion des soins de santé, notamment Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC®, BacterioChek et MicrobioChek utilisés pour la gestion, le suivi et la personnalisation des données et des patients. Depuis 2012, certains produits ABL SA sont marqués CE-IVD. En 2020, ABL SA a obtenu le marquage CE-IVD pour ses tests DeepChek®-HIV ainsi que pour son test UltraGene® Combo2Screen SARS-CoV-2 et pour son test UltraGene® SARS-CoV-2 Multi Variants Deletions V1 et son test UltraGene® Triplex. Les autres produits sont actuellement disponibles à des fins de recherche uniquement.

Contacts :

ETABLISSEMENTS FAUVET-GIREL

+33 (0)1 56 88 20 40

fauvet-girel@ablsa.com

Site : www.fauvet-girel.fr

ADVANCED BIOLOGICAL LABORATORIES SA

+352 2638967640

contact@ablsa.com

Site : www.ablsa.com

The Luxembourg Institute of Health (LIH) and Advanced Biological Laboratories (ABL) are joining forces to predict immune protection against COVID-19 and support long-term vaccination strategies. To this end, the two laboratories have signed a license agreement and a collaboration agreement to provide two in vitro diagnostic solutions to measure neutralizing antibody levels.  

LIH has established a reference viral neutralization assay that measures the activity of neutralizing antibodies against the different SARS-CoV-2 Variants of Concerns.  This assay, realized in a BSL3 laboratory, is the reference assay to provide neutralization titers and predict immune protection against COVID-19 or disease severity. To rationalize long-term COVID vaccination strategies, LIH has also developed a more accessible surrogate variant neutralisation test, which measures neutralizing antibodies binding reflecting their neutralization activities.

This R&D collaboration proposes to establish a service-based product at LIH with the reference variant neutralization assay and to manufacture the surrogate variant neutralisation test for in vitro testing of the neutralization capacity of antibodies against different SARS-CoV-2 variants.

Seeking an accurate diagnostic solution to predict immune protection

Immunity to SARS-CoV-2 induced by natural infection or vaccination reduces the risk of severe infection and affords a degree of protection against reinfection. “It is now clear that neutralizing serum antibodies contributes mainly to this protective role” says Dr Carole Devaux, head of the HIV-Clinical and Translational Research (HIV-CTR) group. “The effectiveness and the duration of protective immunity is challenged by the spread of highly transmissible viral variants that evade vaccine or monoclonal antibodies protection. It is now critical to propose standardized and sensitive tests to assess SARS-CoV-2 immunity and guide vaccination strategies at the personal level “

At LIH, Dr Danielle Perez Bercoff has set-up the reference viral assay used to predict vaccine efficacy in different clinical trials. However, there are few standardized and accurate serological in vitro tests, to date, able to predict the neutralizing activities of antibodies, and available for the different variants of concern. Dr Eveline Santos da Silva and Dr Danielle Perez Bercoff will be in charge at LIH to optimize the surrogate variant neutralization test for this purpose. The collaboration with ABL aims to make a Prove of Concept of the feasibility of such market and to manufacture the surrogate variant neutralisation test.

Pertinent innovation for the health sector

Chalom Sayada, CEO and founder of ABL, adds: “We have been developing web and software-based diagnostic solutions for healthcare for more than 20 years now. Our focus has been on infectious diseases such as HIV, hepatitis and HPV, where we have built a global customer base. With COVID-19, we expanded our operations with the development and CE IVD registration of robust qPCR and Next Generation Sequencing assays for SARS-CoV-2 detection and variants identification, and now look forward to developing innovation for people with one of Luxembourg’s leading healthcare players.”

Helping to quickly roll out efficient measures

The relevance of the project is also central for LIH: “Such a partnership with ABL is extremely valuable for us. As part of our new strategy, we aim to have an impact that positively affects the lives of the patients and this partnership puts us in a position where we can effectively do that,” adds Ulf Nehrbass, CEO of LIH.

A long time collaboration has been established between the research group HIV-CTR and ABL (SPREAD database, subtyping tool COMET) and new service agreements for SARS-CoV2 diagnostics were started in 2020 to support the R&D of ABL. Together with ABL, the research group speculated that a sensitive viral assay able to quantify the neutralizing titers against most VoCs and a surrogate variant neutralization test would be essential for the clinical management of patients in real-time to help to stratify the patients for the different vaccines, especially towards the outgrow of the VOCs.

The collaboration aims to make a Prove of Concept of the feasibility of such market and to manufacture the surrogate variant neutralisation test.

About the Luxembourg Institute of Health (LIH)

The Luxembourg Institute of Health (LIH) is a public biomedical research organization focused on precision health and invested in becoming a leading reference in Europe for the translation of scientific excellence into meaningful benefits for patients.

LIH places the patient at the heart of all its activities, driven by a collective obligation towards society to use knowledge and technology arising from research on patient derived data to have a direct impact on people’s health. Its dedicated teams of multidisciplinary researchers strive for excellence, generating relevant knowledge linked to immune related diseases and cancer.

The institute embraces collaborations, disruptive technology and process innovation as unique opportunities to improve the application of diagnostics and therapeutics with the long-term goal of preventing disease.

Le présent document incorpore par référence le rapport financier annuel relatif à l’exercice clos le 31 décembre 2020 (le « Rapport Financier Annuel ») et le rapport financier semestriel relatif à l’exercice clos le 31 décembre 2021 (le « Rapport Financier Semestriel ») d’ETABLISSEMENTS FAUVET-GIREL, déposés respectivement auprès de l’AMF le 6 avril 2021 et le 28 juillet 2021 et publiés sur le site internet d’ETABLISSEMENTS FAUVET-GIREL le même jour, et complète la note en réponse de la Société (la « Note en Réponse ») relative à l’offre publique d’achat simplifiée initiée par ADVANCED BIOLOGICAL LABORATORIES SA visant les actions d’ETABLISSEMENTS FAUVET-GIREL (l’ « Offre »), visée par l’AMF le 21 décembre 2021 sous le n° 21-536 en application de la décision de conformité du même jour.

Le présent document complète la note d’information (la « Note d’Information ») relative à l’offre publique d’achat simplifiée initiée par ADVANCED BIOLOGICAL LABORATORIES SA visant les actions de la société ETABLISSEMENTS FAUVET-GIREL (l’« Offre »), visée par l’AMF le 21 décembre 2021 sous le n° 21-535 en application de la décision de conformité du même jour.

La présente note en réponse est disponible sur les sites Internet de l’AMF (www.amf-france.org), de la société ETABLISSEMENTS FAUVET-GIREL (www.fauvet-girel.fr) et de la société ADVANCED BIOLOGICAL LABORATORIES SA (www.ablsa.com) et peut être obtenu sans frais auprès d’ETABLISSEMENTS FAUVET-GIREL (42, rue Olivier Métra, bât E1 – 75020 Paris) et de BANQUE DELUBAC & CIE (16 place Saléon Terras – 07160 Le Cheylard).

Conformément aux dispositions de l’article 231-28 du règlement général de l’AMF, les informations relatives aux caractéristiques notamment juridiques, financières et comptables d’ETABLISSEMENTS FAUVET-GIREL feront l’objet d’une note spécifique déposée auprès de l’AMF et mise à la disposition du public au plus tard la veille du jour de l’ouverture de l’offre publique d’achat simplifiée. Un communiqué sera publié pour informer le public des modalités de mise à disposition de ces informations.

La présente note d’information est disponible sur les sites Internet de l’AMF (www.amf-france.org) et de la société ADVANCED BIOLOGICAL LABORATORIES SA (www.ablsa.com) et peut être obtenue sans frais auprès d’ADVANCED BIOLOGICAL LABORATORIES SA (52-54 Avenue du X Septembre – L-2550 Luxembourg) et de BANQUE DELUBAC & CIE (16 place Saléon Terras – 07160 Le Cheylard).

Conformément aux dispositions de l’article 231-28 du règlement général de l’AMF, les informations relatives aux caractéristiques notamment juridiques, financières et comptables d’ADVANCED BIOLOGICAL LABORATORIES SA feront l’objet d’une note spécifique déposée auprès de l’AMF et mise à la disposition du public au plus tard la veille du jour de l’ouverture de l’offre publique d’achat simplifiée. Un communiqué sera publié pour informer le public des modalités de mise à disposition de ces informations.

Le présent projet de note en réponse a été établi et déposé auprès de l’Autorité des marchés financiers (l’« AMF ») le 8 décembre 2021 conformément aux dispositions des articles 231-19 et 231-26 de son règlement général.
Cette offre et le projet de note en réponse restent soumis à l’examen de l’AMF

Le présent projet de note d’information a été établi et déposé auprès de l’Autorité des marchés financiers (l’« AMF ») le 10 novembre 2021 conformément aux dispositions des articles 231-13, 231-16 et 231-18 de son règlement général.
Cette offre et le projet de note d’information restent soumis à l’examen de l’AMF.

Advanced Biological Laboratories (ABL) S.A. and Medsol Corporation  are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Saudi Arabia.

See current channel partners.

Acquisition of a controlling stake in Etablissements Fauvet Girel by Advanced Biological Laboratories

ETABLISSEMENTS FAUVET GIREL (the ” Company “) hereby informs its shareholders that STE PARISIENNE DE CONSTRUCTION ET DE LOCATION (SPACLO), holding 91.47% of the Company’s capital, and seven individuals, jointly holding 5.22% of the capital, have entered into a share purchase and sale agreement under the terms of which the transferors have sold their respective shareholdings to ADVANCED BIOLOGICAL LABORATORIES S.A. (” ABL SA “)

The sale of all shares held by the sellers, i.e., 242,527 shares out of a total of 250,810 shares, representing 96.69% of the Company’s capital and voting rights, was carried out today for a price of 15.90 euros[1] per share, resulting in a value of €3,986,890for 100% of the shares of ETABLISSEMENTS FAUVET GIREL

In accordance with current  regulations, in particular Articles L. 433-3 of the French Monetary and Financial Code and 233-1 2° and 234-2 of the General Regulations of the Autorité des marchés financiers (AMF), ABL SA will file a proposed public tender offer (the ” Offer “) with the AMF at a price of 15.90 euros per share, for all the shares making up the capital of ETABLISSEMENTS FAUVET GIREL that are not held by ABL SA (i.e., 8,189 shares)[2]. The Offer will be made on behalf of the Initiator by Banque Delubac & Cie.

An independent expert will be appointed by the Company to assess the fairness of the financial terms of the Offer in accordance with current regulations. An ad hoc committee will be set up shortly for the purpose of appointing the independent expert and monitoring the latter’s work in accordance with the provisions of Article 261-1 of the General Regulation.

The Offer will not be followed by a compulsory withdrawal procedure as ABL SA intends to maintain the listing of the Company’s shares for the reasons set out below.

The Company’s proposed development of new activities

The Company is a “shell” that has not been active since 2018. The Company no longer holds any assets other than cash. Its last remaining asset (i.e., a flat in the Paris region) was sold on 29 April 2021[3].

ABL SA wishes to develop new activities in the field of genotype-based diagnosis of infectious diseases within the Company.

Once the Offer has been completed, the shareholders of the Company will be asked to approve the transaction in a general meeting, during which the business of Advanced Biological Laboratories Fedialis, a wholly owned subsidiary of ABL SA (” ABL France “), will be transferred to the Company. The listing of the shares that will result from the transfer transactions on which the Company’s shareholders will be asked to vote in a general meeting will be subject to the approval of a prospectus by the AMF.

The transfer of ABL France to the Company and the resulting change in direction of the Company’s business will also be accompanied by a request for an exemption from the filing of a public buyout offer on the basis of Article 236-6 of the AMF’s general regulations.

ABL France is a limited joint stock company with a capital of €2,100,000, whose registered office is located at 5 boulevard de Trèves, 57070 Metz, registered in the Metz Trade and Companies Register under number 811 018 084. ABL France will be acquired by the Company, which will be renamed ABL Diagnostics.

ABL France (a wholly owned subsidiary of ABL SA) is a company specialising in genotype-based diagnostics for infectious diseases. As a manufacturer, provider of expertise and technical protocols, ABL France develops and markets proprietary genotyping diagnostic kits targeting chronic infectious diseases. ABL France has developed the first high-tech genotyping products for AIDS, viral hepatitis and, more recently, tuberculosis. ABL France also develops products for Covid-19 genotyping.

ABL France’s activities are carried out in the United States through its wholly owned subsidiary, ABL DX USA.

ABL France also plans to develop new research and development (R&D) programmes in the fields of molecular scissors, oncology, and rare diseases of infectious origin. ABL France uses a software solution developed and marketed by ABL SA on a non-exclusive basis for its own diagnostic kits.

With regards to the aforementioned transactions, the Company’s shareholders will therefore be asked to vote on the modification of the Company’s corporate purpose to allow the development of these new activities and the change of the Company’s name (i.e., ABL Diagnostics).

Post operations, the Company may also seek investment and external growth opportunities to promote the dynamics of its core business. In this respect, the acquisition of the Company combined with the above-mentioned operations will therefore considerably increase the development options within a regulatory framework consistent with the business dimension of infectious disease diagnostics, which requires sustainable capital. ABL Diagnostics will thus be able to expand its sources of financing and consider, at a later stage, the modalities for an increase in the free float, which could represent up to 30% of the capital depending on market conditions and investor interest.

Appointment of new directors

At today’s meeting, the Board of Directors of the Company proceeded to co-opt the new members to replace the five members representing the sellers.

The Board of Directors is now composed of the following members, who have been appointed on the basis of their competence in the scientific and medical fields as well as the accounting and financial fields.

• Mr Alain Leriche – Belgian national, financier, chartered accountant, auditor, independent director.
• Laure Raffaelli – French national, ABL finance manager, OptimizAdvices director).
• Jean-Christophe Renondin (MD-MBA) – French national, working in the financial field as a venture capitalist (former director of the Caisse des dépôts et consignations in Paris), independent director.
• Ms Noémie Sadoun – French national, working in the field of finance (Veolia).
• Ms Deborah Szafir – French national, working in the pharmaceutical industry (Pierre Fabre), independent director.

It is planned to appoint a sixth director at the next general meeting of the Company called to approve the business transfer operations, with the role being given to:

• Mr Carlos Freixas – Spanish national, international diagnostics expert (formerly of Roche).

The biographies of the new Board members can be found on the Company’s website.

In this new form, The Board of Directors decided to separate the functions of Chairman of the Board of Directors and Chief Executive Officer and appointed Mrs Noémie Sadoun, of French nationality, as Chairman of the Board of Directors, and Mr Ronan Boulmé, of French nationality, currently Director of Regulatory Affairs of ABL France, as Chief Executive Officer.

Expected timeframe

The public offer operations are being conducted with a view to the Initiator filing the draft Offer as soon as possible and the completion of the Offer, subject to the work of the independent expert and the regulatory deadlines for the examination of the draft Offer, at the end of 2021 or the beginning of 2022. The Offeror and the Company will make the required disclosures in this regard in accordance with current regulations.

Subject to the above, ABL SA will initiate the transfer of ABL France’s business to the Company after the completion of the Offer, as early as January or February 2022, with a view to completing the business transfer operations during the first half of 2022.

About Etablissements Fauvet Girel

Etablissements Fauvet Girel is a company listed on Euronext Paris (Compartment C) which no longer carries on any activity as of the date hereof and holds no assets other than residual cash in its accounts.

ETABLISSEMENTS FAUVET GIREL – ISIN code: FR0000063034 – Site: www.fauvet-girel.fr

About Advanced Biological Laboratories (ABL LLC)

Advanced Biological Laboratories (ABL), S.A., is a medical diagnostics company founded in 2000 as a separate spin-off from CRP-Santé (https://www.lih.lu/) Luxembourg.

ABL’s products are marketed towards infectious disease clinicians, virology, and microbiology laboratories, including

• genotyping kits (within ABL France) and software for accredited laboratories (ISO 15189), mainly for microbiology applications (related to HIV, SARS-CoV-2, tuberculosis, HCV, HBV, HPV, CMV, influenza, 16s rRNA, etc.) for genotyping by capillary or high-throughput sequencing (DeepChek®), detection and quantification of DNA and RNA (UltraGene®)
• clinical software applications for infectious disease units.
• computer dashboards and aggregation applications for research and clinical management.

ABL acquired the rights to all EVIVAR MEDICAL’s viral hepatitis B & C assets in 2013 and a custom-made electronic medical record system for infectious diseases from GlaxoSmithKline in 2016. In July 2018, ABL acquired CDL Pharma to develop related CRO services and diagnostic kit manufacturing. In June 2019, ABL established its US subsidiary (AdvancedDx Biological Laboratories) covering the entire North American territory. This subsidiary markets ABL products for Research Use Only (RUO) and Investigational Use Only (IUO), as well as ABL products already registered with the FDA.

ABL offers a comprehensive suite of healthcare management products including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC®, BacterioChek and MicrobioChek used for the management, tracking and personalization of patient data. Since 2012, some ABL products are CE-IVD marked. In 2020, ABL obtained the CE-IVD mark for its DeepChek®-HIV tests as well as for its UltraGene® Combo2Screen SARS-CoV-2 test, its UltraGene® SARS-CoV-2 Multi Variants Deletions V1 test and its UltraGene® Triplex test The other products are currently available for research purposes only.

Contacts:

ETABLISSEMENTS FAUVET GIREL

+33 (0)1 45 06 15 74
gdambrine@fauvet-girel.fr

ADVANCED BIOLOGICAL LABORATORIES S.A.
+352 2638967640
contact@ablsa.com

[1] Subject to a possible adjustment of the sale price linked to the amount of the net assets of ETABLISSEMENTS FAUVET GIREL on the day of the sale of a portion of ETABLISSEMENTS FAUVET GIREL shares.
[2] Excluding 94 treasury shares.
[3] See the Company’s press release dated 10 May 2021.